<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00980746</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-206</org_study_id>
    <secondary_id>EudraCT 2007-002461-12</secondary_id>
    <nct_id>NCT00980746</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy</brief_title>
  <official_title>Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) as Therapy for Patients With Painful Diabetic Neuropathy: a Double-blind, Double-dummy, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the efficacy of eslicarbazepine acetate (ESL)
      as therapy for patients with painful diabetic neuropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain</measure>
    <time_frame>17 weeks</time_frame>
    <description>﻿Endpoint mean pain was defined as the mean of the last 4 available pain scores in the last 7 days of the treatment period. Likewise, baseline mean pain was defined as the mean of the last 4 available pain scores in the last 7 days of the baseline period.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">557</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>ESL 400 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL 400 mg twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESL 800 mg once-daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 600 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eslicarbazepine 600 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 1200 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eslicarbazepine acetate 1200 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ESL 800 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eslicarbazepine acetate 800 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eslicarbazepine acetate</intervention_name>
    <description>Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
    <arm_group_label>ESL 400 mg BID</arm_group_label>
    <arm_group_label>ESL 800 mg QD</arm_group_label>
    <arm_group_label>ESL 600 mg BID</arm_group_label>
    <arm_group_label>ESL 1200 mg QD</arm_group_label>
    <arm_group_label>ESL 800 mg BID</arm_group_label>
    <other_name>Zebinix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral route</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent to participate in the study

          -  Men and women aged 18 years or older

          -  Diagnosis of diabetes mellitus Type 1 or 2

          -  Diagnosis of pain attributed to diabetic neuropathy for more than 1 year prior to
             enrolment

          -  Stable glycemic control: (total glycated haemoglobin [HbA1c] level ≤ 11% at screening)

          -  Cooperation and willingness to complete all aspects of the study

          -  Completion of at least 4 daily diaries during the week preceding randomisation

          -  A minimum average daily pain score of 4 on the Numeric rating pain scale (NRPS) in the
             last 4 diary entries before randomisation.

        Exclusion Criteria:

          -  Pain of other origin that might confound the assessment of neuropathic pain of
             diabetic origin

          -  Significant or unstable medical or psychiatric disorders

          -  Drug or alcohol abuse in the preceding 2 years

          -  Peripheral vascular disease with a history of amputation, except amputation of toes

          -  Severe renal function impairment, as shown by calculated creatinine clearance values &lt;
             30 mL/min at screening

          -  Relevant clinical laboratory abnormalities (e.g., Na+ &lt;130 mmol/L, alanine (ALT) or
             aspartate (AST) transaminases &gt;2.0 times the upper limit of normal, white blood cell
             count (WBC) &lt;2,500 cells/mm3)

          -  Previous participation in any study with eslicarbazepine acetate

          -  Pregnancy or breast feeding

          -  History of hypersensitivity to the investigational products or to drugs with a similar
             chemical structure

          -  History of non-compliance

          -  Likelihood of requiring treatment during the study period with drugs or other
             interventions not permitted by the clinical study protocol.

          -  Participation in a clinical study within 3 months prior to screening

          -  Any clinically significant concomitant condition, which might influence the
             assessments or conduct of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2009</study_first_submitted>
  <study_first_submitted_qc>September 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2009</study_first_posted>
  <results_first_submitted>March 26, 2013</results_first_submitted>
  <results_first_submitted_qc>March 26, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 22, 2013</results_first_posted>
  <last_update_submitted>May 18, 2016</last_update_submitted>
  <last_update_submitted_qc>May 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pain diabetes neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Pain</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Date first subject enrolled: 06 Nov 2007 Date last subject completed: 18 Nov 2008 Randomised and treated: 557. Analyzed for efficacy (per-protocol [PP]): 403. Analyzed for safety: 557.</recruitment_details>
      <pre_assignment_details>During the 2week baseline period,current neuropathic pain drug therapy was discontinued and subjects had to be free of any medication that could affect efficacy(except authorized rescue medication)for 2weeks before start of double-blind study treatment.In case of unbearable pain, this drug-free period could be reduced,but had to be at least 7 days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ESL 1200 mg QD</title>
          <description>Eslicarbazepine acetate (ESL) 1200 mg once daily. ESL tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="P2">
          <title>ESL 400 mg BD</title>
          <description>ESL 400 mg twice daily
ESL tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="P3">
          <title>ESL 600 mg BID</title>
          <description>ESL 600 mg twice daily
ESL tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="P4">
          <title>ESL 800 mg BID</title>
          <description>ESL 800 mg twice daily
ESL tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="P5">
          <title>ESL 800 mg QD</title>
          <description>ESL 800 mg once-daily
ESL tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Placebo
Placebo : oral route</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="92"/>
                <participants group_id="P6" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per-protocol</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="62"/>
                <participants group_id="P5" count="73"/>
                <participants group_id="P6" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="75"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="75"/>
                <participants group_id="P6" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ESL 1200 mg QD</title>
          <description>Eslicarbazepine acetate 1200 mg once daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="B2">
          <title>ESL 400 mg BD</title>
          <description>ESL 400 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="B3">
          <title>ESL 600 mg BID</title>
          <description>Eslicarbazepine 600 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="B4">
          <title>ESL 800 mg BID</title>
          <description>Eslicarbazepine acetate 800 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="B5">
          <title>ESL 800 mg QD</title>
          <description>ESL 800 mg once-daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Placebo
Placebo : oral route</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="89"/>
            <count group_id="B3" value="95"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="92"/>
            <count group_id="B6" value="96"/>
            <count group_id="B7" value="557"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="59"/>
                    <measurement group_id="B6" value="65"/>
                    <measurement group_id="B7" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="50"/>
                    <measurement group_id="B6" value="57"/>
                    <measurement group_id="B7" value="309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain</title>
        <description>﻿Endpoint mean pain was defined as the mean of the last 4 available pain scores in the last 7 days of the treatment period. Likewise, baseline mean pain was defined as the mean of the last 4 available pain scores in the last 7 days of the baseline period.</description>
        <time_frame>17 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ESL 1200 mg QD</title>
            <description>Eslicarbazepine acetate 1200 mg once daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
          </group>
          <group group_id="O2">
            <title>ESL 400 mg BD</title>
            <description>ESL 400 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
          </group>
          <group group_id="O3">
            <title>ESL 600 mg BID</title>
            <description>Eslicarbazepine 600 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
          </group>
          <group group_id="O4">
            <title>ESL 800 mg BID</title>
            <description>Eslicarbazepine acetate 800 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
          </group>
          <group group_id="O5">
            <title>ESL 800 mg QD</title>
            <description>ESL 800 mg once-daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Placebo
Placebo : oral route</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in Mean Pain, Scored Daily on a on an 11-point (0-10) Numeric Rating Pain Scale (NRPS), Where 0 = no Pain and 10 = Worst Possible Pain</title>
          <description>﻿Endpoint mean pain was defined as the mean of the last 4 available pain scores in the last 7 days of the treatment period. Likewise, baseline mean pain was defined as the mean of the last 4 available pain scores in the last 7 days of the baseline period.</description>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="92"/>
                <count group_id="O6" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7546" spread="0.2352"/>
                    <measurement group_id="O2" value="-2.2865" spread="0.2325"/>
                    <measurement group_id="O3" value="-1.6746" spread="0.2312"/>
                    <measurement group_id="O4" value="-1.8353" spread="0.2260"/>
                    <measurement group_id="O5" value="-1.9829" spread="0.2328"/>
                    <measurement group_id="O6" value="-1.5801" spread="0.2311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Treatment-emergent adverse event (TEAEs), i.e. those Adverse events (AEs) starting after the first dose intake until 2 days after the last dose,have been summarized</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ESL 1200 mg QD</title>
          <description>Eslicarbazepine acetate 1200 mg once daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="E2">
          <title>ESL 400 mg BD</title>
          <description>ESL 400 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="E3">
          <title>ESL 600 mg BID</title>
          <description>Eslicarbazepine 600 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="E4">
          <title>ESL 800 mg BID</title>
          <description>Eslicarbazepine acetate 800 mg twice daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="E5">
          <title>ESL 800 mg QD</title>
          <description>ESL 800 mg once-daily
Eslicarbazepine acetate : Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Placebo
Placebo : oral route</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="95"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="89"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="95"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research Section</name_or_title>
      <organization>BIAL – Portela &amp; Ca, SA</organization>
      <phone>351 22 986 6100</phone>
      <email>clinical.trials@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

